Last reviewed · How we verify
NCT06345365
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 3 trial testing mitoxantrone liposome, Ara-Cytarabine and azacitidine in Acute Myeloid Leukaemia in 154 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Zhongnan Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 154 |
| Start date | 18 January 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2028 |
| Sites | 11 locations across China |
Drugs / interventions tested
- mitoxantrone liposome, Ara-Cytarabine and azacitidine — full drug profile →
- Daunorubicin,Ara-Cytarabine, azacitidine — full drug profile →
Conditions studied
- Acute Myeloid Leukaemia — all drugs for Acute Myeloid Leukaemia →
Sponsor
Zhongnan Hospital
Who can join
Adults 18 to 75, any sex, with Acute Myeloid Leukaemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigator proposed to apply the new dosage form of mitoxantrone hydrochloride liposomes to the clinical treatment of AML, while combining with cytarabine and azacitidine to form the MA+AZA treatment regimen(Mitoxantrone liposome +Ara-Cytarabine+Azacitidine), which would provide an optimal induction treatment regimen for patients with primary AML by comparing with the traditional chemotherapy regimen, DA+AZA (Daunorubicin+Ara-Cytarabine+Azacitidine).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06345365
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myeloid Leukaemia
Currently open trials in the same condition.
- NCT07155226 — Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Maligna · Phase 1, PHASE2 · recruiting
- NCT07036250 — Clinical Study of U32 in Patients With Acute Myeloid Leukemia · Phase 1, PHASE2 · recruiting
- NCT06793410 — Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation · Phase 2 · recruiting
- NCT06928909 — Leukemia Adapted Protocol · recruiting
Other Zhongnan Hospital trials
Trials by the same sponsor.
- NCT07515963 — FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. · Phase 2 · not yet recruiting
- NCT07420036 — An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, · EARLY_PHASE1 · not yet recruiting
- NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
- NCT07363330 — A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07460258 — A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06345365 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongnan Hospital
- Last refreshed: 10 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06345365.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing